Abstract
Angiotensin II (AT-II) has been used to target regionally-administered cytotoxic microspheres in patients with intrahepatic tumours. The optimisation of vasoconstrictor targeting requires a knowledge of the blood flow changes induced by agents such as AT-II. We therefore assessed duplex/colour Doppler sonography (DCDS) as a means of evaluating the effects of AT-II infusion on hepatic arterial blood flow (HABF) and arterial resistance in patients with intrahepatic tumours. HABF was measured continuously in nine patients using DCDS before, during and after an infusion of AT-II (15 micrograms in 3 ml of saline over 90 s) via a hepatic artery catheter. In seven patients with less than 30% hepatic replacement by tumour, the baseline level of HABF was 331 +/- 85 ml min-1 (mean +/- s.d.), and this was reduced by 75-80% within 30 s of the start of AT-II infusion. HABF recovered rapidly from the end of the infusion, and increased by up to 20% above the baseline for approximately 2 min. In two patients with greater than 50% hepatic replacement, HABF showed no reduction but rose continuously from the start of AT-II infusion, increasing by a factor of 2-2.5 after 3-4 min. Arterial resistance showed reciprocal changes in all cases. We conclude that DCDS is effective in assessing the temporal changes in hepatic arterial blood flow caused by AT-II. In order to optimise tumour targeting, the injection of microspheres loaded with cytotoxic drugs should be completed before the end of the AT-II infusion. The targeting advantage of AT-II in patients with a high percentage hepatic replacement by tumour should be re-assessed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bengmark S., Hafström L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer. 1969 Jan;23(1):198–202. doi: 10.1002/1097-0142(196901)23:1<198::aid-cncr2820230126>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- Goldberg J. A., Murray T., Kerr D. J., Willmott N., Bessent R. G., McKillop J. H., McArdle C. S. The use of angiotensin II as a potential method of targeting cytotoxic microspheres in patients with intrahepatic tumour. Br J Cancer. 1991 Feb;63(2):308–310. doi: 10.1038/bjc.1991.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hemingway D. M., Angerson W. J., Anderson J. H., Goldberg J. A., McArdle C. S., Cooke T. G. Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II. Br J Cancer. 1992 Nov;66(5):958–960. doi: 10.1038/bjc.1992.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leen E., Goldberg J. A., Robertson J., Sutherland G. R., Hemingway D. M., Cooke T. G., McArdle C. S. Detection of hepatic metastases using duplex/color Doppler sonography. Ann Surg. 1991 Nov;214(5):599–604. doi: 10.1097/00000658-199111000-00010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sasaki Y., Imaoka S., Hasegawa Y., Nakano S., Ishikawa O., Ohigashi H., Taniguchi K., Koyama H., Iwanaga T., Terasawa T. Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer. Cancer. 1985 Jan 15;55(2):311–316. doi: 10.1002/1097-0142(19850115)55:2<311::aid-cncr2820550202>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
- Wagner J. S., Adson M. A., Van Heerden J. A., Adson M. H., Ilstrup D. M. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984 May;199(5):502–508. doi: 10.1097/00000658-198405000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wood C. B., Gillis C. R., Blumgart L. H. A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol. 1976 Sep;2(3):285–288. [PubMed] [Google Scholar]